[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623340":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":26,"studyPopulation":18,"armGroups":27,"interventions":34,"overallOfficials":18,"centralContacts":45,"locations":51,"responsibleParty":66,"collaborators":18,"id":70,"slug":18,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":18,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":18,"studyType":82,"phases":83,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":92,"whyStopped":18,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"The First Affiliated Hospital of Guangzhou Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Perioperative Serious Complications","The proportion of participants who experience serious perioperative complications within 30 days after the procedure, defined as complications of Clavien-Dindo grade III or higher, including events requiring surgical, endoscopic, or radiologic intervention, intensive care management, or resulting in death.","Within 30 days after the procedure",[14],{"measure":15,"description":16,"timeFrame":17},"Successful completion rate of the planned hybrid treatment strategy","Technical feasibility is defined as the proportion of participants in whom the planned hybrid treatment strategy-robot-assisted CT-guided percutaneous intervention followed by non-intubated video-assisted thoracoscopic surgery-is successfully completed without unplanned abandonment of the procedure. Conversion to conventional intubated anesthesia is permitted and will be recorded.","From the start of the percutaneous intervention to completion of the planned hybrid procedure during the same hospitalization, assessed up to 30 days",null,{"allocation":20,"interventionModel":21,"interventionModelDescription":22,"primaryPurpose":23,"observationalModel":18,"timePerspective":18,"maskingInfo":24},"NA","SINGLE_GROUP","This is a prospective, single-arm study in which all enrolled participants receive a predefined hybrid treatment strategy combining robot-assisted percutaneous intervention and non-intubated video-assisted thoracoscopic surgery during the same hospitalization.","TREATMENT",{"masking":25,"maskingDescription":18,"whoMasked":18},"NONE","This is a prospective, single-arm interventional study conducted at a tertiary academic medical center. The study enrolls adult patients with multiple pulmonary nodules, including at least one dominant lesion that meets standard indications for thoracoscopic surgical resection and one or more additional nodules for which complete surgical resection is considered undesirable due to concerns regarding lung parenchymal preservation or procedural risk.\n\nAll participants receive a predefined hybrid treatment strategy during the same hospitalization. Selected secondary pulmonary nodules are managed using robot-assisted CT-guided percutaneous procedures, including localization, biopsy, and\u002For thermal ablation as clinically appropriate. Subsequently, the dominant lesion is resected using non-intubated video-assisted thoracoscopic surgery under spontaneous ventilation anesthesia. Conversion to conventional intubated anesthesia is permitted if clinically indicated.\n\nThe primary focus of this study is to assess perioperative safety and technical feasibility rather than comparative efficacy. Safety is evaluated by monitoring perioperative complications within 30 days after the procedure, while feasibility is assessed based on successful completion of the planned hybrid treatment strategy. Secondary observations include perioperative recovery parameters such as length of hospital stay, postoperative pain, and short-term clinical outcomes.\n\nThis study is designed to provide prospective evidence regarding the clinical applicability of a hybrid, lung parenchyma-preserving approach for the management of multiple pulmonary nodules within the framework of current surgical and interventional practice.",[28],{"label":29,"type":30,"description":31,"interventionNames":32},"Hybrid Robot-Assisted Percutaneous Intervention Plus Non-Intubated VATS","EXPERIMENTAL","Participants in this single-arm study receive a predefined hybrid treatment strategy during the same hospitalization. The intervention consists of robot-assisted CT-guided percutaneous procedures (including localization, biopsy, and\u002For thermal ablation as clinically appropriate) for selected pulmonary nodules, followed by non-intubated video-assisted thoracoscopic surgery for resection of the dominant pulmonary lesion. Conversion to conventional intubated anesthesia is permitted if clinically indicated.",[33],"Procedure: Hybrid Robot-Assisted Percutaneous Intervention and Non-Intubated Video-Assisted Thoracoscopic Surgery",[35],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"PROCEDURE","Hybrid Robot-Assisted Percutaneous Intervention and Non-Intubated Video-Assisted Thoracoscopic Surgery","This intervention consists of a predefined hybrid procedural strategy performed during the same hospitalization. Selected pulmonary nodules are managed using robot-assisted CT-guided percutaneous procedures, including localization, biopsy, and\u002For thermal ablation as clinically appropriate. Subsequently, the dominant pulmonary lesion is resected using non-intubated video-assisted thoracoscopic surgery under spontaneous ventilation anesthesia. Conversion to conventional intubated anesthesia is permitted if clinically indicated.",[29],[41,42,43,44],"Robot-assisted percutaneous ablation","CT-guided percutaneous localization","Non-intubated VATS","NiVATS",[46],{"name":47,"role":48,"phone":49,"phoneExt":18,"email":50},"Yudong Zhang, MD","CONTACT","+86 13168266675","yudongz834@gmail.com",[52],{"facility":53,"status":18,"city":54,"state":18,"zip":18,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"The First Affiliated Hospital of GZMU","Guangzhou","China","CN",{"type":58,"coordinates":59},"Point",[60,61],113.25,23.11667,{"lat":61,"lon":60},[64],{"name":65,"role":48,"phone":49,"phoneExt":18,"email":50},"Yudong Zhang",{"type":67,"investigatorFullName":68,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Jianxing He","Professor, Department of Thoracic Surgery","100623340",false,"NCT07395362","Hybrid Robot-Assisted Percutaneous Ablation and Non-Intubated VATS for Multiple Pulmonary Nodules","A Prospective Single-Arm Study Evaluating the Safety, Feasibility, and Perioperative Recovery of Robot-Assisted Percutaneous Ablation\u002FLocalization Combined With Non-Intubated Video-Assisted Thoracoscopic Surgery for Multiple Pulmonary Nodules","Inclusion Criteria:\n\n1. Age 18 to 85 years at the time of enrollment.\n2. Presence of multiple pulmonary nodules identified on chest computed tomography (CT).\n3. At least one dominant pulmonary lesion meeting standard indications for thoracoscopic surgical resection based on radiologic assessment.\n4. At least one additional pulmonary nodule for which complete surgical resection is considered undesirable due to lung parenchyma preservation concerns or procedural risk, and deemed suitable for robot-assisted CT-guided percutaneous intervention.\n5. Determined by a multidisciplinary team (MDT) to be an appropriate candidate for the predefined hybrid treatment strategy.\n6. Eligible for non-intubated video-assisted thoracoscopic surgery based on preoperative anesthetic evaluation (ASA physical status I-III).\n7. Ability to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n1. Pulmonary nodules located centrally or adjacent to major airways, major vessels, or the heart, where safe percutaneous intervention is not feasible.\n2. Pure ground-glass nodules with a maximum diameter \\\u003C 6 mm, for which active surveillance is recommended.\n3. Clinical evidence of N1\u002FN2 lymph node involvement or distant metastasis.\n4. Severe cardiopulmonary disease, interstitial lung disease, or other conditions that preclude thoracoscopic surgery or anesthesia.\n5. Coagulation disorders or ongoing anticoagulation therapy that cannot be safely discontinued.\n6. Pregnancy or breastfeeding.\n7. Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study assessments.","ALL","18 Years","85 Years",{"count":80,"type":81},30,"ESTIMATED","INTERVENTIONAL",[20],"The goal of this clinical trial is to evaluate the safety and feasibility of a predefined hybrid treatment strategy in patients with multiple pulmonary nodules who require surgical management of at least one dominant lesion. The strategy combines robot-assisted CT-guided percutaneous ablation and\u002For localization with non-intubated video-assisted thoracoscopic surgery (NiVATS) performed during the same hospitalization.\n\nThe main questions this study aims to answer are:\n\nIs the hybrid treatment strategy associated with an acceptable rate of perioperative serious complications?\n\nCan the planned combination of robot-assisted percutaneous intervention and NiVATS be completed successfully in a real-world clinical setting?\n\nParticipants will:\n\nUndergo preoperative evaluation and multidisciplinary assessment;\n\nReceive robot-assisted CT-guided percutaneous ablation and\u002For localization for selected pulmonary nodules;\n\nUndergo non-intubated video-assisted thoracoscopic surgery for resection of the dominant pulmonary lesion;\n\nBe followed for perioperative outcomes and short-term recovery up to 30 days after surgery.",[86],"Multiple Pulmonary Nodules",[88,89,41,90,91],"Multiple pulmonary nodules","Ground-glass nodules","CT-guided intervention","Non-intubated video-assisted thoracoscopic surgery NiVATS","NOT_YET_RECRUITING","2026-02-06",{"date":95,"type":96},"2026-02-09","ACTUAL",{"date":98,"type":81},"2026-02-28",{"date":100,"type":81},"2026-10-01",{"name":5,"class":6},1]